CanSino Biologics (HKG:6185, SHA:688185) will receive a further $17 million grant from Bill & Melinda Gates Foundation for the continued development of the recombinant poliomyelitis vaccine (CS-2036), a Wednesday bourse filing said.
The Chinese biotechnology firm had initially obtained $2 million of funding from the foundation in October 2023.
The further development included clinical research, process development and scale-up, and the development of CS-2036 component combined vaccine candidates
Shares of the company closed over 8% lower on Wednesday.
Price (HKD): $26.10, Change: $-2.3, Percent Change: -8.10%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。